Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 102Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Ovarian Neoplasms 6Neoplasm Metastasis 6Breast Neoplasms, Male 6Neoplasms 5Glioblastoma 5Central Nervous System Neoplasms 5Prostatic Neoplasms 4Gliosarcoma 4Inflammatory Breast Neoplasms 3Glioma 3Brain Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Glioma, Subependymal 2Fallopian Tube Neoplasms 2Ependymoma 2Breast Cancer Female 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Risk Reduction Behavior 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Tamoxifen × Clear all
NCT00492505 2014-01-10

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

National Cancer Institute (NCI)

Phase 2 Unknown
200 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡